(window.webpackJsonp=window.webpackJsonp||[]).push([[7],{340:function(t,e,n){var content=n(347);content.__esModule&&(content=content.default),"string"==typeof content&&(content=[[t.i,content,""]]),content.locals&&(t.exports=content.locals);(0,n(28).default)("fc6c70cc",content,!0,{sourceMap:!1})},346:function(t,e,n){"use strict";n(340)},347:function(t,e,n){var o=n(27),r=n(32),f=n(33),l=n(34),c=n(35),d=n(36),m=n(37),v=n(38),h=n(39),y=n(40),_=n(41),x=n(42),w=n(43),A=n(44),N=n(45),T=n(46),k=n(47),I=n(48),B=n(49),M=n(50),O=n(51),z=n(52),C=o(!1),P=r(f),R=r(l),S=r(c),j=r(d),F=r(m,{hash:"#AvenirNextRegular"}),D=r(v),J=r(h),E=r(y),L=r(_),V=r(x,{hash:"#AvenirNextMedium"}),Y=r(w),G=r(A),H=r(N),K=r(T),Q=r(k,{hash:"#AvenirNextBold"}),U=r(I),W=r(B),X=r(M),Z=r(O),$=r(z,{hash:"#AvenirNextItalic"});C.push([t.i,'@font-face{font-family:"AvenirNextRegular";font-style:normal;font-weight:400;font-display:swap;src:url('+P+");src:url("+P+') format("embedded-opentype"),url('+R+') format("woff2"),url('+S+') format("woff"),url('+j+') format("truetype"),url('+F+') format("svg")}@font-face{font-family:"AvenirNextMedium";font-style:normal;font-display:swap;src:url('+D+");src:url("+D+') format("embedded-opentype"),url('+J+') format("woff2"),url('+E+') format("woff"),url('+L+') format("truetype"),url('+V+') format("svg")}@font-face{font-family:"AvenirNextBold";font-display:swap;src:url('+Y+");src:url("+Y+') format("embedded-opentype"),url('+G+') format("woff2"),url('+H+') format("woff"),url('+K+') format("truetype"),url('+Q+') format("svg")}@font-face{font-family:"AvenirNextItalic";font-display:swap;src:url('+U+");src:url("+U+') format("embedded-opentype"),url('+W+') format("woff2"),url('+X+') format("woff"),url('+Z+') format("truetype"),url('+$+') format("svg")}.text-bold[data-v-85b1dfba]{font-family:"AvenirNextBold",Arial,sans-serif}.content ul[data-v-85b1dfba]{list-style:disc;margin:16px 0;padding-left:20px}.btn[data-v-85b1dfba]{background-color:transparent;background-image:none;border-radius:7px;border:1px solid #003e51;color:#003e51;cursor:pointer;font-family:"AvenirNextBold",Arial,sans-serif;font-size:14px;min-height:51px;min-width:164px;padding:6px 12px}.btn[data-v-85b1dfba]:hover{background-color:#003e51;color:#fff}.btn[data-v-85b1dfba]:focus{box-shadow:0 0 0 2px #45b979}.btn.btn-green-light[data-v-85b1dfba]{background-color:#45b979;border-color:#45b979;color:#fff}.btn.btn-green-light[data-v-85b1dfba]:hover{background-color:#fff;color:#45b979}.btn.btn-disabled[data-v-85b1dfba]{background-color:#45b979;border-color:#45b979;color:#fff;cursor:default;opacity:.8}.btn.btn-disabled[data-v-85b1dfba]:hover{background-color:#fff;color:#45b979}.bottom-notification[data-v-85b1dfba]{color:#4f5f6e;font-family:Arial,sans-serif}.bottom-notification ul[data-v-85b1dfba]{margin:0 0 20px}.bottom-notification ul li[data-v-85b1dfba]{margin-bottom:4px}.bottom-notification p[data-v-85b1dfba]{color:#003e51}.bottom-notification a[data-v-85b1dfba]{color:#45b979;font-size:14px}.notification-title[data-v-85b1dfba]{color:#003e51;line-height:18px;margin-bottom:4px;text-transform:uppercase}',""]),t.exports=C},349:function(t,e,n){"use strict";n.r(e);var o={},r=(n(346),n(10)),component=Object(r.a)(o,(function(){this._self._c;return this._m(0)}),[function(){var t=this,e=t._self._c;return e("div",{staticClass:"bottom-notification content"},[e("h3",{staticClass:"notification-title"},[t._v("\n    INDICATION\n  ")]),t._v(" "),e("ul",[e("li",[t._v("\n      Trumenba is a vaccine indicated for individuals 10 through 25 years of age for active immunization to prevent invasive disease caused by Neisseria meningitidis group B\n    ")])]),t._v(" "),e("h3",{staticClass:"notification-title"},[t._v("\n    IMPORTANT SAFETY INFORMATION\n  ")]),t._v(" "),e("ul",[e("li",[t._v("\n      Trumenba should not be given to anyone with a history of a severe allergic reaction to any component of Trumenba\n    ")]),t._v(" "),e("li",[t._v("\n      Some individuals with weakened immune systems may have a reduced immune response\n    ")]),t._v(" "),e("li",[t._v("\n      Persons with certain complement deficiencies and persons receiving treatments such as SolirisÂ® (eculizumab), are at increased risk for invasive disease caused by Neisseria meningitidis group B even with receipt of vaccination with Trumenba\n    ")]),t._v(" "),e("li",[t._v("\n      Vaccination with Trumenba may not protect all vaccine recipients against N meningitidis group B infections\n    ")]),t._v(" "),e("li",[t._v("\n      Fainting can occur in association with administration of injectable vaccines, including Trumenba\n    ")]),t._v(" "),e("li",[t._v("\n      The most common adverse reactions in adolescents and young adults were pain at injection site, fatigue, headache, and muscle pain\n    ")]),t._v(" "),e("li",[t._v("\n      Data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series\n    ")]),t._v(" "),e("li",[t._v("\n      Tell your health care provider if you are pregnant, or plan to become pregnant\n    ")]),t._v(" "),e("li",[t._v("\n      Ask your health care provider about the risks and benefits of Trumenba. Only a health care provider can decide if Trumenba is right for you or your child\n    ")])]),t._v(" "),e("p",{staticClass:"text-bold"},[t._v("\n    Please see "),e("a",{attrs:{href:"https://labeling.pfizer.com/ShowLabeling.aspx?id=1796",target:"_blank"}},[t._v("full Prescribing Information")])])])}],!1,null,"85b1dfba",null);e.default=component.exports}}]);